Directory Profile

Dr. Tom Nolin is a tenured Associate Professor in the Department of Pharmacy & Therapeutics, and in the Department of Medicine Renal-Electrolyte Division at the University of Pittsburgh. Dr. Nolin is the Associate Dean for Research and Sponsored Programs, and he is the Director of the University of Pittsburgh Small Molecule Biomarker Core mass spectrometry facility (

Dr. Nolin is an NIH funded investigator whose primary research focuses on developing an understanding of the impact of kidney disease and renal replacement therapy (RRT) on nonrenal metabolism and transport pathways and corresponding effects on drug exposure (pharmacokinetics) and response (pharmacodynamics). Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of clinical-translational studies. He served as chair of the Kidney Health Initiative workgroup to assess pharmacokinetics during RRT and as co-chair of the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup. Dr. Nolin has published over 150 manuscripts and book chapters and has presented more than 175 scientific abstracts and invited talks. He serves on the editorial board of the Clinical Journal of the American Society of Nephrology, and as an Editor of DiPiro's Pharmacotherapy: A Pathophysiologic Approach textbook. Dr. Nolin is a Fellow of the American College of Clinical Pharmacy, the American College of Clinical Pharmacology, and of the American Society of Nephrology.

The research focus of the Nolin laboratory includes characterizing the impact of kidney disease and renal replacement therapy on drug exposure (clinical pharmacokinetics) and response (pharmacodynamics), evaluating the functional expression of drug metabolizing enzymes and transporters, developing novel quantitative analytical techniques, and assessing the implications of using various kidney function estimating equations on drug eligibility, selection, and dosing. The long-range goal of our research is to identify the mechanisms by which kidney disease contributes to alterations in these drug elimination pathways, to understand the impact of these alterations on drug response and patient outcomes, and ultimately, to use this information in the development of strategies to optimize drug use in patients with kidney disease.

Click on the PubMed icon underneath the photo for a complete list.

Casal MA, Ivy SP, Beumer JH, Nolin TD. Impact of removing race from GFR-estimating equations on anticancer drug dosing and eligibility: A retrospective analysis of National Cancer Institute phase I clinical trial participants. Lancet Oncol 2021;22(9):1333-1340. PMCID: PMC8425175.

Bouchard J, Shepherd G, Hoffman RS, Gosselin S, Roberts DM, Li Y, Nolin TD, Lavergne V, Ghannoum M. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: Systematic review and recommendations from the EXTRIP Workgroup. Crit Care 2021;25(1):201. PMCID: PMC8194226.

Ghannoum M, Berling I, Lavergne V, Roberts DM, Galvao T, Hoffman RS, Nolin TD, Lewington A, Doi K, Gosselin S. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. Kidney Int 2021;100(4):720-736. PMID: 34358487.

Tuey SM, Atilano-Roque A, Charkoftaki G, Thurman JM, Nolin TD, Joy MS. Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia. Xenobiotica 2021;51(6):657-667. PMID: 33870862.

Franchetti Y, Nolin TD. Application of individualized PBPK modeling of rate data (iPBPK-R) to evaluate the effect of hemodialysis on nonrenal clearance pathways. J Clin Pharmacol 2021;61(6):769-781. PMID: 33459400.

Mowry JB, Shepherd G, Hoffman RS, Lavergne V, Gosselin S, Nolin TD, Vijayan A, Kielstein JT, Roberts DM, Ghannoum M. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP Workgroup. Pharmacotherapy 2021;41(5):463-478. PMID: 33660266.

Davis BH, Sangha R, Dillon C, Brown TM, Narayan R, Beasley M, McElderry T, Nolin TD, Limdi NA. Risk factors for major hemorrhage among patients receiving dabigatran across the spectrum of CKD not requiring dialysis therapy. Am J Kidney Dis 2021;78(1):151-153. PMID: 33276038.

Wong A, Hoffman RS, Walsh SJ, Roberts DM, Gosselin S, Bunchman TE, Kebede S, Lavergne V, Ghannoum M, for the EXTRIP workgroup including Alhatali B, Anseeuw K, Berling I, Bouchard J, Bird S, Bouchard J, Chin P, Doi K, Galvao T, Goldfarb D, Hassanian H, Hoegberg L, Kallab S, Kielstein J, Li Y, Macedo E, MacLaren R, Megarbane B, Mowry J, Nolin TD, Osterman M, Peng A, Roy JP, Vijayan A, Wood D, Yates C. Extracorporeal treatment for calcium channel blocker poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2021;59(5):361-375. PMID: 33555964.

Feng Z, Chen M, Xue Y, Liang T, Chen H, Zhou Y, Nolin TD, Smith RB, Xie XQ. MCCS: A novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. Brief Bioinform 2021;22(2):946-962. PMCID: PMC7665328.

Franchetti Y, Nolin TD. Dose optimization in kidney disease: Opportunities for PBPK modeling and simulation. J Clin Pharmacol 2020;60(S1):S36-S51. PMID: 33205428.

Berling I, King JD, Shepherd G, Hoffman RS, Alhatali B, Lavergne V, Roberts DM, Gosselin S, Wilson G, Nolin TD, Ghannoum M. Extracorporeal treatment for chloroquine, hydroxychloroquine, and quinine poisoning: Systematic review and recommendations from the EXTRIP Workgroup. J Am Soc Nephrol 2020;31(10):2475-2489. PMID: 32963091.

Kimber C, Zhang S, Johnson C, West RE, Prokopienko AJ, Mahnken JD, Yu AS, Hoofnagle AN, Ir D, Robertson CE, Miyazaki M, Chonchol M, Jovanovich A, Kestenbaum B, Frank DN, Nolin TD, Stubbs JR. Randomized, placebo-controlled trial of rifaximin therapy for lowering gut-derived cardiovascular toxins and inflammation in CKD. Kidney360 2020;1(11)1206-1216. PMCID: PMC8315698.

Jawale CV, Ramani K, Li D, Coleman BM, Oberoi RS, Kupul S, Lin L, Desai JV, Delgoffe GM, Lionakis MS, Bender FH, Prokopienko AJ, Nolin TD, Gaffen SL, Biswas PS. Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease. Sci Transl Med 2020;12(548):eaay5691. PMCID: PMC7879380.

Prokopienko AJ, West RE, Schrum DP, Stubbs JR, Leblond FA, Pichette V, Nolin TD. Metabolic activation of flavin monooxygenase-mediated trimethylamine-N-oxide formation in experimental kidney disease. Sci Rep 2019;9(1):15901. PMCID: PMC6828678.

Prokopienko AJ, West RE, Stubbs JR, Nolin TD. Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease. J Pharm Biomed Anal 2019;174:618-624. PMCID: PMC6677161.

Franchetti Y, Nolin TD. Simultaneous assessment of hepatic transport and metabolism pathways with a single probe using individualized PBPK modeling of 14CO2 production rate data. J Pharmacol Exp Ther 2019;371(1):151-161. PMCID: PMC6750580.

Crisamore KR, Nolin TD, Coons JC, Empey PE. Engaging and empowering stakeholders to advance pharmacogenomics. Clin Pharmacol Ther 2019;106(2):305-308. PMID: 31241758.

Casal MA, Nolin TD, Beumer JH. Estimation of kidney function in oncology: Implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol 2019;14(4):587-595. PMCID: PMC6450339.

Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD. Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis. Clin J Am Soc Nephrol 2019;14(2):261-267. PMCID: PMC6390920.

Ramezani A, Nolin TD, Barrows IR, Serrano MG, Buck GA, Regunathan-Shenk R, West RE, Latham PS, Amdur R, Raj DS. Gut colonization with methanogenic archaea lowers plasma trimethylamine N-oxide concentrations in apolipoprotein e-/- mice. Sci Rep 2018;8(1):14752. PMCID: PMC6170401.

Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM. Use of physiologically-based pharmacokinetic modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates. Clin Pharmacol Ther 2019;105(3):719-729. PMCID: PMC8246729.

Johnson C, Prokopienko AJ, West RE III, Nolin TD, Stubbs JR. Decreased kidney function is associated with enhanced hepatic flavin monooxygenase activity and increased circulating trimethylamine N-oxide concentrations in mice. Drug Metab Dispos 2018;46(9):1304-1309. PMID: 29915157.

Ghannoum M, Hoffman RS, Gosselin S, Nolin TD, Levergne V, Roberts DM. Use of extracorporeal treatments in the management of poisonings. Kidney Int 2018;94(4):682-688. PMID: 29958694.
Choi YJ, Zhou D, Barbosa ACS, Niu Y, Guan X, Xu M, Ren S, Nolin TD, Liu Y, Xie W. Activation of constitutive androstane receptor ameliorates renal ischemia-reperfusion induced kidney and liver injury. Mol Pharmacol 2018;93(3):239-250. PMCID: PMC5801556.

Hudson JQ, Nolin TD. Pragmatic use of kidney function estimates for drug dosing: The tide is turning. Adv Chronic Kidney Dis 2018;25(1):14-20. PMID: 29499882.

Roumelioti ME, Trietley G, Nolin TD, Ng YH, Xu Z, Alaini A, Figueroa R, Unruh ML, Argyropoulos CP. Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: A meta-analysis of published studies. Nephrol Dial Transplant 2018;33(6):1025-1039. PMID: 29186592.

Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM. Effect of chronic kidney disease on nonrenal elimination pathways: A systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19 and OATP. Clin Pharmacol Ther 2018;103(5):854-867. PMCID: PMC5947523.

Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of regular or extended hemodialysis and hemodialfiltration on plasma oxalate concentrations in patients with end-stage renal disease. Kidney Int Rep 2017;2(6):1050-1058. PMCID: PMC5733827.

Prokopienko AJ, Nolin TD. Microbiota-derived uremic retention solutes: Perpetrators of altered nonrenal drug clearance in kidney disease. Expert Rev Clin Pharmacol 2018;11(1):71-82. PMCID: PMC5979269.

Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC, Wanner C, for Conference Participants including Amann K, Banerjee D, Bansal N, Boriani G, Bunch J, Chan CT, Charytan DM, Conen D, Friedman AN, Genovesi S, Holden RM, House AA, Jadoul M, Jardine AG, Johnson DW, Jun M, Labriola L, Mark PB, McCullough PA, Nolin TD, Potpara TS, Pun PH, Ribeiro ALP, Rossignol P, Shen JI, Sood MM, Tsukamoto Y, Wang AY, Weir MR, Wetmore JB, Wranicz JK, and Yamasaki H. Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Eur Heart J 2018;39(24):2314-2325. PMCID: PMC6012907.